Analysis: Retractions and controversies over coronavirus research show the scientific process is working
Severe scrutiny of two major papers, including one about the effectiveness of hydroxychloroquine, is part of science's normal process of self-correction.
The Latest: WHO ending hydroxycholorquine trial for COVID
WHO says a review of the interim results showed hydroxychloroquine and lopinavir/ritonavir “produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care.”…
Watch 8:10
How doctors are innovating to treat COVID-19
One of the reasons COVID-19 presents such a significant global medical challenge is that there are few effective therapies for it so far. As cases fill hospital beds across many parts of the country, doctors and scientists are coming up…
Watch 3:11
News Wrap: FDA revokes approval for hydroxychloroquine as COVID-19 treatment
In our news wrap Monday, the U.S. Food and Drug Administration withdrew emergency approval for hospitals to use hydroxychloroquine to treat COVID-19. The FDA said the malaria drug is unlikely to be effective against the coronavirus. Meanwhile, infections continue to…
The Food and Drug Administration said the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus.
In our news wrap Thursday, Virginia Gov. Ralph Northam announced that the statue will be removed from Richmond's well-known "Monument Avenue," and said that the state can no longer showcase a cause that sought to preserve slavery. Also, business closings…
Several authors of a large study that raised safety concerns about malaria drugs for coronavirus patients have retracted the report. They say independent reviewers weren't able to verify information that's been widely questioned by other scientists.
So it was this past week when he took very personally a scientific study that should give pause to anyone thinking of following Trump's lead and ingesting a potentially risky drug for the coronavirus. He branded the study's researchers, financed in…
President Trump joined a Republican Senate luncheon Tuesday, where he defended his reported use of controversial antimalarial medication hydroxychloroquine. He also said he would temporarily waive regulations that could complicate business openings or slow economic growth. Meanwhile, senators from the…
Additional Support Provided By:
